Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

CT Open to Enrollment

Serranator OCT: Understanding the Mechanism of Action of Serration Angioplasty by Serranator Versus Conventional Balloon Angioplasty for below-the Knee (BTK) Artery Disease Using Optical Coherence Tomography (OCT)

The purpose of this prospective randomized trial is to evaluate the serration angioplasty effect in below the knee arteries with calcified plaque when the Serranator Serration Angioplasty Balloon is used as compared to a conventional balloon angioplasty.

Conventional balloon angioplasty is a regularly used approach. The Serranator Angioplasty Nalloon is U.S. Food and Drug Administration (FDA) approved and commercially available.

Boomerang-Pivotal Multicenter Trial of the Boomerang Catheter for Percutaneous Deep Vein Arterialization (pDVA)

The purpose of the trial is to find out if an investigational device called the “Boomerang Catheter System,” containing Boomerang Catheter and Boomerang Power Controller works for a new use in the leg and to monitor the safety in treating blockages in the arteries located behind and below the knee down to the small arteries located at the joint of the leg and foot in patients suffering from low blood flow to the lower leg.

Esprit BTK Post-Approval Study (PAS)

The purpose of this research is to assess the continued safety and efficacy of the Esprit BTK system, which was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of narrowed arteries below the knee in patients with Chronic Limb-Threatening Ischemia (CLTI).

Participants may enroll in the study if this stent is used during their procedure. 

Study participation will last for three years, with follow-up visits (after the procedure) at 30 days, 90 days, 180 days, 1 year, 2 years, and 3 years.

Elegance: Drug-Eluting Registry-Real-World Treatment of Lesions in the Peripheral Vasculature

The purpose of this study is to collect data on the use of commercially approved Boston Scientific drug-eluting devices used to treat peripheral vascular disease (PAD) to understand how these devices are being used in a routine hospital setting. We hope to potentially improve patient outcomes in the future as well as to understand how patient outcomes compare across diverse patient populations. The study data will also be used to continue monitoring the safety of these devices.

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

This clinical trial is designed for men and women with stage 4 squamous and non-squamous (NSCLC) who have not received prior systemic therapy for the advanced disease.
   
The purpose of this study is to evaluate the safety and tolerability of EIK1001 with pembrolizumab and chemotherapy in participants with histologically confirmed Stage 4 non-squamous or squamous NSCLC.

Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance

This clinical trial is for men and women who have been diagnosed with clonal cytopenias of uncertain significance (CCUS) that is clinically significant.

The purpose of this study is to learn whether luspatercept is successful in improving blood counts in patients with clonal cytopenias of uncertain significance (CCUS). Luspatercept is a U.S. Food and Drug Administration (FDA) -approved drug for myelodysplastic syndrome (MDS) but is not approved for CCUS.

A prospective, multicenter, single-arm, non-randomized clinical study designed to evaluate the safety and effectiveness of the Citadel Embolization Device

The purpose of this study is to evaluate the safety and effectiveness of the investigational Stryker Citadel Embolization Device for use in the treatment of patients with an aneurysm in the brain. A brain (cerebral) aneurysm is a bulging, weak area in the wall of an artery that supplies blood to the brain.

This device is an investigational device that has not been approved by the U.S. Food & Drug Administration (FDA) for treatment of this type of aneurysm. 

Implantation Mycoses in Immunocompromised Patients: a retrospective review of disease course and treatment efficacy

The primary objective of this retrospective review is to assess the disease course of implantation mycoses in immunocompromised patients when compared to patients without immunocompromise. The secondary objective is to assess demographic factors associated with patients with this diagnosis within our patient population.

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

Terbinafine is a common oral medication used for moderate to severe nail onychomycosis. On the terbinafine package insert, it states that terbinafine can reduce clearance of caffeine by 19%. However, the clinical effects of this finding in patients have yet to really be studied. The investigators of this study hypothesize that there would be significant changes in blood pressure or heart rate in patients consuming caffeine while taking terbinafine.